162368-01-6

Basic information

• Product Name: 1-(4-ACETYLPIPERIDINO)ETHAN-1-ONE
• Synonyms: 1-(4-ACETYLPIPERIDINO)ETHAN-1-ONE;Piperidine, 1,4-diacetyl- (9CI);1-(4-Acetylpiperidino)ethan-1-one ,97%;1,4-Diacetylpiperidine;1-(1-acetylpiperidin-4-yl)ethan-1-one;1,1'-(Piperidine-1,4-diyl)diethanone;1-(1-Acetylpiperidin-4-yl)ethanone
• CAS NO: 162368-01-6
• Molecular Formula: C9H15NO2
• Molecular Weight: 169.22
• Product Categories: ACETYLGROUP
• Mol File: 162368-01-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 308.9°Cat760mmHg
• Flash Point: 137.7°C
• Appearance: /
• Density: 1.057g/cm³
• Vapor Pressure: 0.000659mmHg at 25°C
• Refractive Index: 1.474
• Storage Temp.: 2-8°C
• PKA: -1.36±0.40(Predicted)
• CAS DataBase Reference: 1-(4-ACETYLPIPERIDINO)ETHAN-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-ACETYLPIPERIDINO)ETHAN-1-ONE(162368-01-6)
• EPA Substance Registry System: 1-(4-ACETYLPIPERIDINO)ETHAN-1-ONE(162368-01-6)

Safety Data

• Hazard Codes: Harmful:
• Hazardous Substances Data: 162368-01-6(Hazardous Substances Data)

Usage

General Description

1-(4-Acetylpiperidino)ethan-1-one, also known as N-Acetylpiperidin-4-yl methyl ketone, is a synthetic organic compound belonging to the class of piperidine derivatives. It is commonly used as an intermediate in the production of pharmaceuticals and other organic compounds. This chemical is known for its potent and selective inhibition of monoamine oxidase type A (MAO-A), making it useful in the development of drugs for the treatment of various neurodegenerative and psychiatric disorders. It is also used in research and development for its ability to modulate neurochemical pathways. Additionally, it has potential applications in the field of medicinal chemistry for the synthesis of novel therapeutic agents. However, it is important to note that 1-(4-Acetylpiperidino)ethan-1-one should be used with caution due to its potential health risks and environmental hazards.

InChI:InChI=1/C9H15NO2/c1-7(11)9-3-5-10(6-4-9)8(2)12/h9H,3-6H2,1-2H3

Upstream product

• 25503-90-6 1-acetyl-piperidine-4-carboxylic acid 
• 498-94-2 isonipecotic acid 
• 213886-98-7 1-acetyl-N-methoxy-N-methylpiperidine-4-carboxamide 
• 75-16-1 methylmagnesium bromide 

Downstream Products

• 953044-73-0 1-(4-(2-(5-(3-methylthieno[3,2-b]pyridin-7-ylthio)-3-phenoxypyridin-2-ylamino)thiazol-4-yl)piperidin-1-yl)ethanone 
• 953130-97-7 1-(4-(2-(3-phenoxy-5-(thieno[3,2-b]pyridin-7-ylthio)pyridin-2-ylamino)thiazol-4-yl)piperidin-1-yl)ethanone 
• 953044-77-4 1-(4-(2-(3-phenoxy-5-(thieno[2,3-d]pyrimidin-4-ylthio)pyridin-2-ylamino)thiazol-4-yl)piperidin-1-yl)ethanone 
• 1065604-63-8 1-(4-(2-(5-(3-hydroxypropylthio)-3-phenoxypyridin-2-ylamino)thiazol-4-yl)piperidin-1-yl)ethanone 
• 953046-49-6 methyl 3-(6-(4-(1-acetylpiperidin-4-yl)thiazol-2-ylamino)-5-phenoxypyridin-3-ylthio)propanoate 
• 953131-47-0 1-(4-(2-(3-phenoxy-5-(pyridin-2-ylthio)pyridin-2-ylamino)thiazol-4-yl)piperidin-1-yl)ethanone 
• 953130-88-6 1-(4-(2-(5-bromo-3-phenoxypyridin-2-ylamino)thiazol-4-yl)piperidin-1-yl)ethanone 
• 162368-02-7 1-(1-acetylpiperidin-4-yl)-2-bromoethanone 

Relevant articles and documents

NOVEL GPR119 AGONIST COMPOUNDS

The present invention relates to novel compounds of formula (I), process for preparation of the same and composition comprising these compounds.

2-AMINOPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS

Provided are compounds having the Formula (I) or salts thereof, wherein: L is O, S, SO, SO2, CHOH, C(O), or CH2; D2 is CR12 or N; R2 is aryl, heteroaryl, saturated or partially unsaturated cycloalkyl, or saturated or partially unsaturated heterocyclyl (optionally substituted with oxo), wherein said aryl, heteroaryl, cycloalkyl and heterocyclyl are monocyclic or bicyclic and are further optionally substituted with one or more groups independently selected from C1-C6 alkyl, F, Cl, Br, I, CF3, CN, OR6, C(=O)R6, C(=O)OR6, O(CH2)nC(=O)OR6, C(=O)NR6R7, NO2 and (1-6C alkyl)OR6; R3 is H, Br, OR6, SR6, C(O)OR6, C(O)NR6R7, C(O)R6, heteroaryl, or C1-C6 alkyl substituted with one or more groups independently selected from Vn-aryl, Vn-OR6, Vn- C(=O)OR6 and Vn-NR6R7; R11 is H or Cl; and R13 is N-(1 -6C alkanoyl)piperidin-4-yl; that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.